צבעי הסוואה ישראל - עברית - Ministry of Health

צבעי הסוואה

ביטון יוסי - צבעי הסוואה לפנים

פרבליפ 10 ישראל - עברית - Ministry of Health

פרבליפ 10

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

סטטור 5 ישראל - עברית - Ministry of Health

סטטור 5

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 5 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia ) or mixed dyslipidaemia ( type iib ) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. hormozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatment are not appropriate.

סטטור 10 ישראל - עברית - Ministry of Health

סטטור 10

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 10 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

סטטור 20 ישראל - עברית - Ministry of Health

סטטור 20

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 20 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

סטטור 40 ישראל - עברית - Ministry of Health

סטטור 40

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 40 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

טרקליר 62.5 מג ישראל - עברית - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

קלופידוגרל טבע ישראל - עברית - Ministry of Health

קלופידוגרל טבע

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

קלוד ישראל - עברית - Ministry of Health

קלוד

unipharm ltd, israel - clopidogrel as hydrogen sulfate - טבליה - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : patients suffering from myocardial infarction (from a few days until less than 35 days ) ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ) in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg . clo